Mtt Nguyen1,2,3, H Lindegaard4, O Hendricks5,6, N Friis-Møller1. 1. a Department of Infectious Diseases , Odense University Hospital , Odense , Denmark. 2. b Institute of Clinical Research , University of Southern Denmark , Odense , Denmark. 3. c OPEN, Odense Patient data Explorative Network , Odense University Hospital , Odense , Denmark. 4. d Department of Rheumatology , Odense University Hospital , Odense , Denmark. 5. e Department of Rheumatology , King Christian 10th Hospital for Rheumatic Diseases , Graasten , Denmark. 6. f Institute of Regional Research , University of Southern Denmark , Odense , Denmark.
Abstract
OBJECTIVE: This study investigates predictors of influenza and pneumococcal vaccine coverage among rheumatoid arthritis (RA) patients, and explores possible differences according to type of RA therapy. METHOD: RA patients from two clinics in the region of Southern Denmark were informed about the survey during scheduled follow-up visits. The questionnaire included questions concerning previous influenza and pneumococcal vaccine uptake, attitudes about vaccination, and socio-demographic factors. Factors associated with recalled vaccine uptake were assessed by multivariate logistic regression. RESULTS: A total of 192 RA patients completed the survey, 134 (70%) of whom were women and 90 (47%) were aged ≥ 65 years. Sixty-seven patients (35%) received conventional disease-modifying anti-rheumatic drugs (cDMARDs) and 125 (65%) combination therapy with biological disease-modifying anti-rheumatic drugs (bDMARDs). Self-reported uptake of vaccination against seasonal influenza ever was 59% overall; 57% among patients receiving cDMARDs and 61% in patients receiving bDMARDs. Self-reported vaccine uptake against pneumococcal diseases was only 6% overall. Older age, educational level, and information and recommendation by a specialist or general physician were positively associated with influenza vaccine uptake, while there was no significant difference in vaccine uptake according to RA treatment type. Reasons for not being vaccinated included fear of adverse effects, lack of information and recommendation, and perception of good health. CONCLUSION: We observed a low prevalence of influenza and in particular of pneumococcal vaccinations among RA patients receiving immunosuppressive drugs, with no difference in coverage according to type of RA therapy. More population-specific evidence to support recommendations is required to increase awareness among patients and physicians.
OBJECTIVE: This study investigates predictors of influenza and pneumococcal vaccine coverage among rheumatoid arthritis (RA) patients, and explores possible differences according to type of RA therapy. METHOD:RApatients from two clinics in the region of Southern Denmark were informed about the survey during scheduled follow-up visits. The questionnaire included questions concerning previous influenza and pneumococcal vaccine uptake, attitudes about vaccination, and socio-demographic factors. Factors associated with recalled vaccine uptake were assessed by multivariate logistic regression. RESULTS: A total of 192 RApatients completed the survey, 134 (70%) of whom were women and 90 (47%) were aged ≥ 65 years. Sixty-seven patients (35%) received conventional disease-modifying anti-rheumatic drugs (cDMARDs) and 125 (65%) combination therapy with biological disease-modifying anti-rheumatic drugs (bDMARDs). Self-reported uptake of vaccination against seasonal influenza ever was 59% overall; 57% among patients receiving cDMARDs and 61% in patients receiving bDMARDs. Self-reported vaccine uptake against pneumococcal diseases was only 6% overall. Older age, educational level, and information and recommendation by a specialist or general physician were positively associated with influenza vaccine uptake, while there was no significant difference in vaccine uptake according to RA treatment type. Reasons for not being vaccinated included fear of adverse effects, lack of information and recommendation, and perception of good health. CONCLUSION: We observed a low prevalence of influenza and in particular of pneumococcal vaccinations among RApatients receiving immunosuppressive drugs, with no difference in coverage according to type of RA therapy. More population-specific evidence to support recommendations is required to increase awareness among patients and physicians.
Authors: Hanley J Ho; Yi-Roe Tan; Alex R Cook; Gerald Koh; Tat Yean Tham; Eve Anwar; Grace Shu Hui Chiang; May O Lwin; Mark I Chen Journal: Am J Public Health Date: 2019-10-17 Impact factor: 9.308
Authors: Viviane Ta; Orit Schieir; Marie-France Valois; Ines Colmegna; Carol Hitchon; Louis Bessette; Glen Hazlewood; Carter Thorne; Janet Pope; Gilles Boire; Diane Tin; Edward C Keystone; Vivian P Bykerk; Susan J Bartlett Journal: ACR Open Rheumatol Date: 2022-03-29
Authors: Patricia Richi; Jose Yuste; Teresa Navío; Laura González-Hombrado; Marina Salido; Israel Thuissard-Vasallo; Ana Jiménez-Díaz; Jesús Llorente; Laura Cebrián; Leticia Lojo; Martina Steiner; Tatiana Cobo; María Dolores Martín; Marta García-Castro; Patricia Castro; Santiago Muñoz-Fernández Journal: Vaccines (Basel) Date: 2021-02-28
Authors: Sebastian Eduardo Sattui; Jean W Liew; Jonathan S Hausmann; Julia F Simard; Jeffrey A Sparks; Kevin Kennedy; Emily Sirotich; Michael Putman; Tarin T Moni; Akpabio Akpabio; Deshiré Alpízar-Rodríguez; Francis Berenbaum; Inita Bulina; Richard Conway; Aman Dev Singh; Eimear Duff; Karen L Durrant; Tamer A Gheita; Catherine L Hill; Richard A Howard; Bimba F Hoyer; Evelyn Hsieh; Lina El Kibbi; Adam Kilian; Alfred Hyoungju Kim; David F L Liew; Chieh Lo; Bruce Miller; Serena Mingolla; Michal Nudel; Candace A Palmerlee; Jasvinder A Singh; Namrata Singh; Manuel Francisco Ugarte-Gil; John Wallace; Kristen J Young; Suleman Bhana; Wendy Costello; Rebecca Grainger; Pedro M Machado; Philip C Robinson; Paul Sufka; Zachary S Wallace; Jinoos Yazdany; Carly Harrison; Maggie Larché; Mitchell Levine; Gary Foster; Lehana Thabane; Lisa G Rider Journal: RMD Open Date: 2021-09